title: Intravitreal ranibizumab for diabetic macular oedema: 1-year experiences in a clinical setting.
authors.forename: Troels
authors.initials: T
authors.lastname: Brynskov
authors.forename: Caroline Schmidt
authors.initials: CS
authors.lastname: Laugesen
authors.forename: Torben Lykke
authors.initials: TL
authors.lastname: Sørensen
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000503:physiopathology; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000503:physiopathology; D000069579:Ranibizumab; D012189:Retrospective Studies; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D000069579:Ranibizumab; D042461:Vascular Endothelial Growth Factor A; C467484:VEGFA protein, human; C517652:hemoglobin A1c protein, human